Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Multidimensional Longitudinal Assessment of Oral Mucositis Burden and Functional Impact in Head and Neck Cancer Patients Undergoing Radiotherapy or Chemoradiotherapy: A Retrospective and Exploratory Observational Study.

Cancers·2026

Same author

Exploratory Analysis of the Neutrophil-to-Lymphocyte Ratio (NLR) and Mucositis Severity in Head and Neck Cancer Patients Undergoing Radiotherapy-Based Treatment: A Retrospective Study.

Journal of clinical medicine·2026

Same author

Late peritoneal carcinomatosis from cutaneous melanoma mimicking ovarian cancer.

Melanoma research·2025

Same author

Longitudinal prediction of drug response in high-grade serous ovarian cancer organoid cultures aligning with clinical responses.

Journal of advanced research·2025

Same author

Novel De Novo <i>BRCA2</i> Variant in an Early-Onset Ovarian Cancer Reveals a Unique Tumor Evolution Pathway.

International journal of molecular sciences·2025

Same author

Correction: Colomba et al. Haemodynamic Forces: Emerging Markers of Ventricular Remodelling in Multiple Myeloma Cardiovascular Baseline Risk Assessment. <i>Cancers</i> 2024, <i>16</i>, 3081.

Cancers·2024

Search research articles

Related Experiment Video

Updated: Mar 14, 2026

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Stem Cell Transplantation in Multiple Myeloma.

Massimo Offidani¹, Silvia Gentili¹, Francesca Gay²

¹Clinica di Ematologia AOU Ospedali Riuniti di Ancona, Ancona. Italy.

Current Cancer Drug Targets

|September 24, 2016

Summary

High-dose therapy and autologous stem cell transplant are standard for multiple myeloma. New drugs significantly improve response rates and support continuous therapy for long-term disease control.

Keywords:

ASCT Stem cell transplantation carfilzomib ixazomib.multiple myeloma proteasome inhibitors

More Related Videos

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

Related Experiment Videos

Last Updated: Mar 14, 2026

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

Area of Science:

Hematology
Oncology
Clinical Therapeutics

Background:

High-dose therapy (HDT) with autologous stem cell transplantation (ASCT) is the standard for multiple myeloma (MM) in patients under 65.
Recent advancements include novel agents like thalidomide, lenalidomide, and bortezomib, enhancing treatment efficacy.

Purpose of the Study:

To review the evolution of HDT and ASCT in multiple myeloma.
To discuss the impact of novel agents on response rates and long-term disease control.
To explore the role of newer therapies and ongoing trials evaluating ASCT.

Main Methods:

Review of recent clinical trials and therapeutic strategies in multiple myeloma.
Analysis of the efficacy of novel agents (thalidomide, lenalidomide, bortezomib) in induction, consolidation, and maintenance phases.
Examination of preliminary data on next-generation proteasome inhibitors (carfilzomib, ixazomib).

Main Results:

Novel drug combinations significantly increase response rates post-induction therapy and ASCT.
Consolidation and maintenance strategies with these agents support continuous therapy for improved outcomes.
Next-generation proteasome inhibitors show potential for achieving molecular remission.

Conclusions:

Novel agents have substantially improved outcomes in multiple myeloma treatment.
Continuous therapy is a key strategy for long-term disease management.
Ongoing trials are crucial to redefine the role and timing of ASCT in the era of novel therapies.